Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
Top Cited Papers
Open Access
- 30 September 2009
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 4 (9), e7258
- https://doi.org/10.1371/journal.pone.0007258
Abstract
The stem cell factor receptor, KIT, is a target for the treatment of cancer, mastocytosis, and inflammatory diseases. Here, we characterise the in vitro and in vivo profiles of masitinib (AB1010), a novel phenylaminothiazole-type tyrosine kinase inhibitor that targets KIT. In vitro, masitinib had greater activity and selectivity against KIT than imatinib, inhibiting recombinant human wild-type KIT with an half inhibitory concentration (IC50) of 200±40 nM and blocking stem cell factor-induced proliferation and KIT tyrosine phosphorylation with an IC50 of 150±80 nM in Ba/F3 cells expressing human or mouse wild-type KIT. Masitinib also potently inhibited recombinant PDGFR and the intracellular kinase Lyn, and to a lesser extent, fibroblast growth factor receptor 3. In contrast, masitinib demonstrated weak inhibition of ABL and c-Fms and was inactive against a variety of other tyrosine and serine/threonine kinases. This highly selective nature of masitinib suggests that it will exhibit a better safety profile than other tyrosine kinase inhibitors; indeed, masitinib-induced cardiotoxicity or genotoxicity has not been observed in animal studies. Molecular modelling and kinetic analysis suggest a different mode of binding than imatinib, and masitinib more strongly inhibited degranulation, cytokine production, and bone marrow mast cell migration than imatinib. Furthermore, masitinib potently inhibited human and murine KIT with activating mutations in the juxtamembrane domain. In vivo, masitinib blocked tumour growth in mice with subcutaneous grafts of Ba/F3 cells expressing a juxtamembrane KIT mutant. Masitinib is a potent and selective tyrosine kinase inhibitor targeting KIT that is active, orally bioavailable in vivo, and has low toxicity.Keywords
This publication has 39 references indexed in Scilit:
- Kit mutations in cancer and their treatment with protein kinase inhibitorsDrugs of the Future, 2008
- An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxicJCI Insight, 2007
- Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumorsLaboratory Investigation, 2006
- Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cellsBlood, 2006
- Stem cell factor and its receptor c-Kit as targets for inflammatory diseasesEuropean Journal of Pharmacology, 2006
- Signaling by Kit protein-tyrosine kinase—The stem cell factor receptorBiochemical and Biophysical Research Communications, 2005
- Role of Tyrosine Kinase Inhibitors in Cancer TherapyJournal of Pharmacology and Experimental Therapeutics, 2005
- Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinibBlood, 2005
- Autocrine regulation of cord blood–derived human mast cell activation by IL-10Journal of Allergy and Clinical Immunology, 2001
- Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar developmentNature, 1998